{
  "docId": "019dd923-5e88-73ef-bd5c-f812573a947a",
  "docSlug": "eea7524c557036f4",
  "documentTitle": "2020 Air Street Capital The State of AI Report 2020",
  "authorId": "AirStreetCapital",
  "authorName": "Air Street Capital",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "vc_research",
  "sourceTypeLabel": "VC research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 85,
  "pageCount": 177,
  "prevPage": 84,
  "nextPage": 86,
  "slideType": "industry_trends",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 7,
  "notes": "The slide illustrates the 'platform strategy' model where parent AI companies spin off specific drug assets into independent entities.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "logo_grid",
    "process_diagram"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5c-f812573a947a/85",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5c-f812573a947a#slide-85",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Platform technologies give rise to promising drug assets that are spun off into independent entities following the successful “asset focused” company building approach of the life science sector and its investors.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-47c5-73ac-aa68-3771b9dc4702",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.8,
        "x": 0.1,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Flowchart showing Recursion to CereXis and Atomwise to X37 spin-offs",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "880ba881-84e4-45b9-bc22-78c3440dc763",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "image",
      "text": "Recursion, Healx, Exscientia, Insitro, Atomwise logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67746753-5939-4fb4-82c1-e4d34cefb51c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "metric",
      "text": "$121M Series C, $56M Series C, $60M Series C, $143M Series B, $123M Series B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81dbe970-0b4b-4e4e-9929-9a81bf6436ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Funding amount: $239M",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-47c5-73ac-aa68-3bdb96dd3375",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "Platform technologies give rise to promising drug assets that are spun off into independent entities following the successful “asset focused” company building approach of the life science sector and its investors.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2a69995-65a7-42fb-a5b5-f1aae858654f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "title",
      "text": "AI-first drug discovery startups raising mega rounds and fulfilling their “platform strategies”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7a6f22f-b09e-4c01-86c2-75a427ec1c84",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "471ac015-ba9b-4bcf-bad8-14d4d587cd34",
      "evidence": "The components mention a 'platform strategies' and 'asset focused' company building approach which hints at the AIDA model's Attention, Interest, Desire, and Action stages.",
      "confidence": 0.7
    },
    {
      "name": "Concrete Language",
      "slug": "concrete-language",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "019dd95a-0fd5-7148-8ecf-6bd69a90d122",
      "evidence": "$239M mega round figure.",
      "confidence": 75
    }
  ],
  "frameworks": [
    {
      "name": "breakup-spinoff",
      "slug": null,
      "matchId": "10999e37-7235-4cf6-b9e7-5b9fa572e5a5",
      "evidence": "The slide explicitly describes spinning off drug assets into independent entities.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 129,
      "from": 10,
      "beatId": "019dd95a-0682-776c-8e34-ed2a8f38a754",
      "arcName": "The Triple Take",
      "arcSlug": "triple-take",
      "beatName": "The Facts (What)",
      "beatSlug": "triple-take-the-facts-what",
      "evidence": "Research, Talent, Industry sections inventory what happened in AI in 2020.",
      "position": 1,
      "confidence": 60,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    },
    {
      "to": 129,
      "from": 10,
      "beatId": "019dd95a-0682-776c-8e34-fc384f439bba",
      "arcName": "The Mountain",
      "arcSlug": "mountain",
      "beatName": "Rising Action",
      "beatSlug": "mountain-rising-action",
      "evidence": "Research, Talent and Industry sections build momentum of AI progress.",
      "position": 2,
      "confidence": 40,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 89,
      "from": 83,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "019dd95a-07fe-70ce-8d3d-0f7fddb1083f",
      "evidence": "Phase 1 trial, EUR250M Exscientia deal, mega rounds, MELLODDY, LabGenius.",
      "position": 10,
      "objective": "Show pharma validating AI-first drug discovery",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 75,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}